Research and analysis
Table 3a: Fetal Loss
Updated 7 January 2021
Download CSV 1.67 KB
| Table 3a: Fetal Loss | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fetal Loss | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Carbamazepine | Gabapentin | Lamotrigine | Levetiracetam | Oxcarbazepine | Phenobarbital | Phenytoin | Pregabalin | Topiramate | Valproate | Zonisamide |
| Meta-analyses | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Veroniki et al 2017a | OR 1.25 (0.73,2.36) | - | OR 1.38 (0.70,2.88) | OR 2.47 (0.50,10.15) | OR 1.66 (0.50,4.50) | OR 0.90 (0.44,1.93) | OR 1.50 (0.85,2.91) | - | OR 23.58 (1.18,549.60) | OR 1.83 (1.04,3.45) | -? |
| Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | N=3911 | Not set | N=2540 | N=28 | N=567 | N=407 | N=618 | Not set | N=2 | N=2612 | Not set |
| Pregnancy Registries | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Vajda et al 2018 | 4.70% | - | 3.67% | 1.55% | 5.26% | - | 2.38% | - | 1.96% | 3.17% | - |
| Vs WWE unexposed | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | N=404 | Not set | N=382 | N=129 | N=19 | Not set | N=42 | Not set | N=51 | N=284 | Not set |
| Kerala Pregnancy Registry | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Trivedi et al 2018 | 5.80% | - | 8.30% | 6.40% | 8.90% | 3.60% | 7.80% | - | 45.40% | 7.10% | - |
| vs WWE unexposed | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | N=465 | Not set | N=48 | N=63 | N=56 | N=138 | N=129 | Not set | N=11 | N=322 | Not set |
| Birth Registers | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Bech et al 2014 | 14.40% | - | 13.60% | - | 15.00% | - | - | - | - | 15.8%* | Not set |
| Vs | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| WWE unexposed | N=409 | Not set | N=1128 | Not set | N=413 | Not set | Not set | Not set | Not set | N=474 | Not set |
| ?Artama et al 2013 | 11.6 (all) | - | No cases | No cases | 11.5 (all) | - | No cases | - | - | 10.6 (all) | - |
| Finland | 9.2 (mono) | Not set | Not set | Not set | 13.2 (mono) | Not set | Not set | Not set | Not set | 9.9 (mono) | Not set |
| Vs WWOE (no AED exposure) | 24.0 (poly) | Not set | Not set | Not set | 6.1 (poly) | Not set | Not set | Not set | Not set | 1.3 (poly) | Not set |
| Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | N=1292 (all) | Not set | Not set | Not set | N=695 (all) | Not set | Not set | Not set | Not set | N=944 (all) | Not set |
| Not set | 1084 (mono) | Not set | Not set | Not set | 532 (mono) | Not set | Not set | Not set | Not set | 706 (mono) | Not set |
| Fujii et al 2013 | Not set | 9.80% | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Not set | N=223 | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Not set | (71epilepsy) | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Others | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Winterfeld et al 2016 | Not set | Not set | Not set | Not set | Not set | Not set | Not set | 15.10% | Not set | Not set | Not set |
| Vs unexposed | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | N=139 | Not set | Not set | Not set |
| ?Ornoy et al 2008 | - | - | - | - | - | - | - | - | 11.30% | Not set | Not set |
| Vs non-teratogen exposed women | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | N=52 | Not set | Not set |
| * Increased risk driven by high dose VPA (>750mg/.day) | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |
| Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set | Not set |